Join X4 Pharmaceuticals for a virtual investor event featuring Peter E. Newburger, MD (UMass Chan Medical School) and Jean Donadieu, MD, PhD (Trousseau Hospital, Paris) to review interim results from an ongoing Phase 2 clinical trial exploring the use of mavorixafor as a once-daily oral treatment in patients with chronic neutropenia (CN).

The data to be presented will include hematological results from participants treated with either mavorixafor monotherapy or mavorixafor in combination with stable doses of injectable granulocyte colony-stimulating factor (G-CSF). Physician expert commentary on the clinical results and the high unmet need in CN will also be included as part of the event.

The company plans to initiate a global, pivotal Phase 3 clinical trial in the current quarter that aims to evaluate the efficacy, safety, and tolerability of oral once-daily mavorixafor (with or without G-CSF) in people with congenital or acquired primary autoimmune and idiopathic chronic neutropenia who are experiencing recurrent and/or serious infections.

A live question and answer session will follow the formal presentations.